Background {#Sec1}
==========

About 50 million Europeans live with multimorbidity and the number is likely to continue rising \[[@CR1]\]. Hence, general practitioners and many patients have to deal with the challenges of multimorbidity, and the multimedication that is frequently associated with it, on a daily basis \[[@CR2]\]. Multimorbidity and multimedication are therefore a research priority in health care. The risk of drug-drug interactions in individual patients increases with the number of co-existing diseases and the number of (prescribed) medicines taken \[[@CR3]\]. Depending on the individual patient's conditions and on interactions between drugs and diseases, multimedication increases the risk of unwanted outcomes and serious harm \[[@CR4]\]. It has been recommended that a distinction should be made between adverse drug reactions (ADRs) and adverse drug events (ADEs) \[[@CR5]\]. ADRs are defined as "an *appreciable* harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product; ADRs usually predict hazard from future administration and warrant prevention, or specific treatment, or alteration of the dosage regimen, or withdrawal of the product" \[[@CR6]\]. ADEs are defined as "a *potentially* harmful effect resulting from an intervention related to the use of a medicinal product, which constitutes a hazard and may or may not be associated with a clinically appreciable adverse reaction and/or an abnormal laboratory test or clinical investigation, as a marker of an adverse reaction." \[[@CR5]\].

In the general population, the prescription of medicinal products with anticholinergic properties has risen by about 40% over the last 10 years \[[@CR7]\]. Older age is known to increase the likelihood of being prescribed anticholinergic medicinal products because they are used to alleviate symptoms that often occur in later life, such as urinary incontinence, and sleep disorders \[[@CR8]\]. As multimedication tends to increase anticholinergic burden in the elderly, the risk of ADRs is particularly high in medicinal products with anticholinergic effects. This is particularly true when a medicinal product with strong anticholinergic properties like amitriptyline is used, or when anticholinergic burden accumulates due to multiple prescriptions \[[@CR9]\]. Another risk factor for anticholinergic prescriptions is institutionalization \[[@CR10]\].

In 1961, amitriptyline was introduced to the US market as a tricyclic antidepressant (TCA), and it is still prescribed regularly for major depression \[[@CR11]\]. It has been approved in more than 56 countries worldwide and is sold under the brand names Saroten, Elavil, and Endep, among many others \[[@CR12]\]. In 2008, it was the third most frequently prescribed antidepressant in Germany, at 94 million defined daily doses (DDD) \[[@CR13]\]. In addition to major depressive disorder, amitriptyline is used to treat other forms of depression, chronic pain, migraine, anxiety disorders \[[@CR11]\], fibromyalgia \[[@CR14]\], neuropathic pain \[[@CR15]\], interstitial cystitis \[[@CR16]\], nocturnal enuresis \[[@CR17]\], eating disorders, and post-herpetic neuralgia \[[@CR18]\].

Amitriptyline inhibits the reuptake of the neurotransmitters serotonin and norepinephrine into the presynaptic neuron by blocking their noradrenaline and serotonin transporters \[[@CR19]\]. It also has an affinity for the muscarinic, histaminergic, and adrenergic systems. This affinity is considered significant for most of the effects of amitriptyline \[[@CR19]\]. Nicotinic anticholinergic receptors (nAChR) are made up of 5 out of 17 subunits \[[@CR20]\]. These receptors occur mostly on the cells of skeletal muscles, autonomous ganglia, and the CNS, and control neuromuscular transmission. Muscarinic anticholinergic receptors (mAChR) are divided into the subtypes M1-M5 and are mostly located in the central nervous system (CNS), heart, gastric tract, genitourinary tract, and respiratory tract. They control neuronal excitement, memory, learning, heart rate, analgesia, and extrapyramidal motor activity. Broadly speaking, ACh effects can be divided into periphery functions (control of skeletal muscles, autonomous nervous system, parasympathetic, enteral nervous system), and functions in the CNS (sleep-awake-rhythm, regulation, impulsion, vigilance, learning, memory) \[[@CR20]\].

Commonly observed ADRs when taking anticholinergic medicines such as amitriptyline are constipation, dry mouth, dry eyes, tachycardia, urinary retention, agitation, confusion, delirium, falls, hallucinations, and cognitive dysfunction \[[@CR21]\]. The following ADRs have been specifically reported for amitriptyline: vision problems, dizziness, sedation, sleepiness, somnolence, drowsiness, tremor, gastralgia, increased appetite, fatigue, asthenia, slow down, and sexual dysfunction. However, not all of these symptoms are caused by muscarinergic inhibition alone \[[@CR11]\].

Anticholinergic ADRs are both underestimated and frequently overlooked in clinical management \[[@CR21], [@CR22]\]. Even though they are common, they are often regarded as "unavoidable" and as part of the aging process or disease course \[[@CR23]\]. Failure to identify ADRs can lead to "prescribing cascades" \[[@CR24], [@CR25]\].This may result in the prescription of another medicinal product by the physician, or the increased use of over-the-counter products (OTC), rather than the discontinuation or dose adjustment of the responsible medicinal products \[[@CR26]\]. With advancing age, an impeded ability to metabolize drugs increases the risk of impairment from anticholinergic burden \[[@CR27], [@CR28]\]. There is growing evidence to suggest that medicines with anticholinergic properties, such as amitriptyline, may cause serious physical and cognitive impairment in the elderly population \[[@CR29]\]. Current research into amitriptyline concentrates mostly on its benefits and harms in relation to a single indication (e.g., depression \[[@CR11]\]). We, in contrast, aim to investigate ADRs to amitriptyline across all indications. The objective of this systematic review and meta-analysis is thus to explore and quantify the frequency and severity of ADRs to amitriptyline vs. placebo in randomized controlled trials (RCTs) of adult humans across all indications, as well as in healthy individuals.

Methods {#Sec2}
=======

This systematic review and meta-analysis will be conducted in accordance with the PRISMA statement \[[@CR30]\].

Aims {#Sec3}
----

To assess ADRs caused by amitriptyline compared with placebo across indications, and in healthy subjectsTo quantify their frequencyTo quantify their severityTo quantify anticholinergic ADRsTo assess ADEs caused by amitriptyline compared with placebo across indications, and in healthy subjectsTo identify factors that influence the frequency of ADRs and ADEs (e.g., age (mean per trial), dose, gender (proportion per trial), indication)To examine the way ADRs and ADEs are described in the RCT under review (e.g., reporting individual reactions vs. reporting one overall number, active vs. passive assessment, subjective vs. objective assessment).

Search strategy {#Sec4}
---------------

We systematically searched multiple electronic databases including MEDLINE, Embase, PsycINFO, PsycLIT, Psyndex, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception. We combined free text searches with controlled terms such as Placebo AND (Amitriptyline OR Amitriptylines OR Amineurin OR Amitrip OR Amitriptylin OR Amitrol OR Anapsique OR Damilen OR Domical OR Elavil OR Endep) AND Randomized controlled trials (for the complete search strategy see Additional file [1](#MOESM1){ref-type="media"}).

We will perform citation analysis (forward and backward citation searches) on the studies included in Web of Science (including SCI - Science Citation Index Expanded, BIOSIS Citation Index, BIOSIS Previews, Current Contents Connect, Medline), and hand search the reference lists of systematic reviews. Furthermore, we will search the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) databases for unpublished approval studies. Additionally, we will ask the major manufacturers of amitriptyline and other experts for information on further relevant RCTs.

We will search the clinical trial registries [ClinicalTrials.gov](http://clinicaltrials.gov), the International Standard Randomized Controlled Trial Number Register (ISRCTN), and the WHO International Clinical Trials Registry Platform (ICTRP) for unpublished studies.

Study selection {#Sec5}
---------------

Titles and abstracts of retrieved studies will be entered into Covidence© and independently screened for eligibility by two reviewers (MSB, ETT). Inclusion and exclusion criteria are provided in Table [1](#Tab1){ref-type="table"}. Table 1Inclusion and exclusion criteria for study selectionPICOS frameworkInclusion criteriaExclusion criteriaPopulationAdult humans, age ≥ 18 any ethnicity, any sex, any indication, or healthyNot applicableInterventionAmitriptyline monotherapy: any dose, frequency, duration, and oral mode of administration (tablets, capsules or liquid form)Amitriptyline in combination with another active therapy, topical use of amitriptylineComparatorPassive placebo (an inert substance that may mimic the ADRs of amitriptyline, i.e., nocebo effects).Comparing amitriptyline with active drugs or other forms of therapyOutcomeQuantification of ADRs for each group, e.g., absolute numbers (frequency and severity (mean/sd)), associated with amitriptyline (i.e., negative effects):(a) caused by its anticholinergic properties and negative effects(b) not caused by anticholinergic propertiesNo outcomes relating to adverse drug reactions.Study designRandomized, double-blind, placebo-controlled trials (RCTs) with ≥ 100 subjects in total for the amitriptyline and placebo arm at baseline: no limitation on publication date, language, setting, time of follow up. Only the first period of crossover trials will be extracted (to avoid carry-over effects \[[@CR31]\]. We will include trials with more than two arms, as long as we can identify an amitriptyline and a placebo arm.Any other study designType of publicationFull publicationAbstract, conference presentation, provisional papers without complete results

Full texts will be obtained for all potentially eligible studies. The two reviewers will then independently determine eligibility based on inclusion and exclusion criteria. Previous to the assessment, a native speaker will translate full texts that are only available in languages other than English or German. Kappa statistics will be calculated to evaluate inter-observer agreement. Any disagreement over eligibility will be resolved through discussion with a third reviewer (CM). The detailed selection process will be shown in a PRISMA flow chart in the full review.

Appraisal of methodological quality {#Sec6}
-----------------------------------

The two review authors (MSB, ETT) will use the risk of bias (RoB) tool provided by Cochrane \[[@CR32]\] to independently evaluate the risk of bias in eligible studies. Characteristics will be tabulated, and any disagreement between the two reviewers will be resolved by discussion with a third (CM and/or SES). The results of the RoB evaluation will be used in a sensitivity analysis.

Data extraction {#Sec7}
---------------

In order to carry out a pilot calibration exercise, we have selected 20 studies from a subsample of 40 studies included in the Cochrane Review "Amitriptyline versus placebo for major depressive disorder" \[[@CR11]\]. We will develop and calibrate a standardized, electronic data extraction sheet and manual on the basis of the following data: Study metadata: authors, year, title, language, funding, country, setting, and objective (indication (Table [2](#Tab2){ref-type="table"}), disease or symptom under review)Study design: type of randomization (e.g., individual or cluster-randomized), number of study arms, crossover, washout, type of blinding (single or double blinded)Population: age (mean per trial), gender (proportion per trial), sample size, baseline characteristics (including comorbidity and multimorbidity), completion ratesIntervention: dose, frequency of dose delivery, days of treatment, and mode of application of amitriptyline, personalized dosage forms (e.g., maximum dosage), titration, intervention adherence, and concomitant medicationComparator: passive placeboOutcomes: type of ADR (e.g., anticholinergic symptoms (Table [3](#Tab3){ref-type="table"})) and other ADRs not commonly considered to be anticholinergic (Table [4](#Tab4){ref-type="table"}), outcome reported subjectively (e.g., assessment scale) or measured objectively (e.g., measurement of salivation), type of data collection (e.g., systematically assessed or sporadically reported), time of measurement, length of follow-up, frequency of ADRs (number or proportion of subjects who have experienced an ADR), severity (e.g., mean, standard deviation) of ADRs, type and number of any reported ADEs (e.g., falls, fall-related fractures, deaths)Table 2Indications for amitriptylineSystemIndicationPainPsychiatryDepression, anxiety disorder, bulimia nervosaNeurologyDepression with headache, headache, prophylaxis of migraine, prophylaxis of chronic tension-type headache, neuropathic pain, narcolepsy, pathological crying or laughingGastroenterologyIrritable bowel syndrome, interstitial cystitisRheumatologyFibromyalgiaToxicologyMedication-overuse headache, ciguatera poisoningSource of data: *Martindale: The Complete Drug Reference* \[[@CR33]\]Table 3Anticholinergic (antimuscarinic) adverse drug reactions to amitriptylineSystemAggregated variablesSymptomGastrointestinal tract asDry mouth-related symptomsDry mouth, difficulty chewing, difficulty swallowing, difficulty speakingDigestion-related symptomsConstipationGenitourinary tractGenitourinary-related symptomsUrinary retentionEye and adnexaVision-related symptomsBlurred vision, disturbances in accommodation, and adaptationSkinThermoregulation related symptomsHot dry skin, hyperthermia, anidrosisCardiovascular systemCardiovascular-related symptomsTachycardia, palpitations, tachyarrhythmiaNervous system1. Fatigue-related symptomsFatigue2. Attention-related symptomsInability to concentrate, confusion, disorientation3. Memory-related symptomsMild amnesia, memory impairment4. Restlessness-related symptomsExcitement, restlessness, agitation5. Coordination-related symptomsAtaxia, hyperreflexiaSource of data: *Martindale: The Complete Drug Reference* \[[@CR33]\], Collamati et al. 2016 \[[@CR29]\]Table 4Non-anticholinergic adverse drug reactions to amitriptylineSystemSymptomGastrointestinal tractSour or metallic tasteStomatitisGastric irritationNausea and vomitingHypersensitivity reactionsUrticariaAngioedemaPhotosensitizationCholestatic jaundiceBlood disorders such as eosinophiliaBone-marrow depressionThrombocytopeniaLeucopeniaAgranulocytosisEndocrine systemTesticular enlargementGynecomastiaBreast enlargementGalactorrhoeaSexual dysfunctionChanges in blood sugar concentrationsHyponatremia associated with inappropriate secretion of antidiuretic hormoneOther adverse effectsIncreased appetite with weight gain (or occasional anorexia with weight loss)SweatingSource of data: *Martindale: The Complete Drug Reference* \[[@CR33]\]

To ensure data extraction is reliable, one reviewer will extract the data (MSB), and another will verify it (ETT). As we do not expect authors of studies published more than 10 years ago to respond to inquiries, we will only contact authors of studies published in 2009 or later in case of missing data, and then only when contact details (e-mail address) are provided in the publication. As research has shown that about 30% of trial authors are unreachable and 40% or more do not respond to emails, even after several reminders \[[@CR34]\], we have decided that if no reply is forthcoming, or the message cannot be delivered, we will not try to contact the author again. The analysis will also include available data for studies published in 2008 or earlier.

Outcomes {#Sec8}
--------

The primary outcome will be the frequency of anticholinergic ADRs as a binary outcome (absolute number of patients with/without any anticholinergic ADRs) in amitriptyline vs. placebo groups. For this purpose, we will separately retrieve the absolute number of anticholinergic ADRs (Table [3](#Tab3){ref-type="table"}) for each type of reaction and for both treatment groups.

We generated the classification scheme by extracting ADRs in concern to the general population from *Martindale: The Complete Drug Reference* \[[@CR33]\]and supplemented them with further reactions that are typical of an older population by using Collamati et al. \[[@CR29]\]. The resulting list contained 39 items. In order to prioritize the symptoms on the list, an experienced clinical pharmacologist (SH) first rated them for specificity with regard to anticholinergic ADRs by differentiating between symptoms that are unequivocally caused by the inhibition of muscarinergic signaling \[[@CR35], [@CR36]\], and those that are not. Amitriptyline can also cause potassium channel blockades \[[@CR37]\], peripheral alpha blockades \[[@CR38]\], norepinephrine reuptake blockades \[[@CR39]\], and inhibit histamine receptors \[[@CR40]\], and sodium channels \[[@CR41]\], all of which potentially cloud the clinical presentation of anticholinergic ADRs. The items on the list also needed to be distinguished from intoxication \[[@CR42], [@CR43]\]. Subsequently, a list of symptoms was drawn up, which then became the anticholinergic ADRs under study. The list consists of 26 ADRs in six organ systems. ADRs that were deemed to be sufficiently similar were pooled in groups of aggregated ADRs, such as vision-related symptoms (see Table [3](#Tab3){ref-type="table"}).

Should the reported ADRs not allow the overall proportion of patients with/without anticholinergic symptoms to be calculated (e.g., when several symptoms occur in one patient, and ADRs are reported for each symptom), we will select the anticholinergic symptom that is most commonly reported. For example, if dry mouth is reported as the most frequent ADR in most of the studies, it will be selected as the primary outcome. Secondary outcomes will be the frequency and severity of any pre-specified anticholinergic and non-anticholinergic ADRs (Table [3](#Tab3){ref-type="table"} and Table [4](#Tab4){ref-type="table"}). Additionally, we will look for any other ADRs and ADEs (e.g., falls and deaths) that are reported in the studies. For this purpose, we will separately retrieve the absolute number of ADRs/ADEs, as well as the group sizes, for each reaction and for both treatment groups. We will then classify the reactions according to the classification provided in Table [3](#Tab3){ref-type="table"} and Table [4](#Tab4){ref-type="table"}.

Data synthesis {#Sec9}
--------------

Firstly, we will describe the data trial wise in terms of study characteristics such as study design, participants, dosing, harms detection, and others. Secondly, we will use forest plots to graphically display the frequency, nature, and severity of the ADRs, along with their confidence intervals, for each trial. We will provide a quantitative synthesis of findings from the included studies using the random-effects model with inverse variance weighting and the DerSimonian-Laird estimator to assess between-trial heterogeneity \[[@CR44]\]. For each study, we will provide summaries of intervention effects by calculating odds ratios (OR) for dichotomous outcomes (such as the ADRs) and standardized mean differences for continuous outcomes (such as the severity of ADRs), along with their 95% confidence intervals. We do not expect to be able to measure time-to-event outcomes.

In order to assess publication bias, we will separately use funnel plots and the Egger regression test \[[@CR45]\] for each outcome.

We expect the number of eligible studies to be high enough to permit us to perform a meta-analysis. However, as we expect trials to report a range of different outcome measures, we will assess comparability before conducting a quantitative synthesis.

Statistics {#Sec10}
----------

Between-trial heterogeneity will be assessed by interpreting its magnitude relative to the scale on which the combined effect is reported, and by calculating the *I*^2^ statistic. When studies are sufficiently homogeneous, we will pool the results using a random-effects meta-analysis with standardized mean differences for continuous outcomes and odds ratios for binary outcomes, and we will calculate 95% confidence intervals and 2-sided *p* values for each outcome. We will use the DerSimonian-Laird estimator to assess between-trial heterogeneity \[[@CR44]\]. Whenever more than five studies are included in the meta-analysis and the outcomes are binary, confidence intervals will be adjusted using the methods proposed by Hartung and Knapp \[[@CR46]--[@CR50]\]. Meta-regression will be used to explain heterogeneity at different time points, and for each indication and mode of administration. We will conduct sensitivity analyses based on study quality and the type of outcome reporting (objective vs. patient reported). We will use forest plots to illustrate the meta-analysis graphically, and will assess evidence of publication bias by means of funnel plots, and by assessing the skewness of the standardized deviates \[[@CR51]\]. All analyses will be performed in R version 3.6.1 or higher \[[@CR52]\].

### Planned sensitivity and subgroup analyses {#Sec11}

We will test the robustness of our results in sensitivity analyses that take into account the risk of bias as well as parameters of reporting quality.

For the subgroup analysis, we will look at mean age per trial. Provided enough studies are available, we will set the cutoff to ≥ 65 years for older/younger adults and ≥ 80 years for very old vs. younger and older adults. We will additionally perform subgroup analyses based on the proportion of males per trial, average duration of the treatment (≤ 1 week, ≥ 1 week, ≥ 4 weeks), average dosage (\< 50 mg, 50--99 mg, 100--150 mg, \> 150 mg), and indication. Assuming it is possible, we will also base the analyses on the proportion of frail patients per trial, proportion of disabled patients per trial and multimorbidity (≥ 3 diseases on average per trial vs. \< 3 diseases on average per trial).

Discussion {#Sec12}
==========

The results of this review will quantify the frequency of anticholinergic ADRs in adults taking amitriptyline compared with placebo for all indications and provide information on the most common adverse drug reactions and associated symptom patterns. Current evidence on anticholinergic effects is often based on observational data (e.g., \[[@CR53], [@CR54]\]), which may be biased, as they cannot distinguish anticholinergic symptoms from disease symptoms and nocebo effects \[[@CR55]\]. In the meta-analysis of Ruxton et al. that studied the anticholinergic side effects of antidepressants in a total 124,286 participants, data were derived mostly from prospective or retrospective cohorts \[[@CR54]\].

A major strength of our multiple-indication review of randomized placebo controlled trials is the design of our study. The first of these is the restriction to the studies with placebo group controls for disease-related symptoms and nocebo effects. Secondly, including studies of all conditions increase the power to detect rare ADRs, and small but important increases in common symptoms. RCTs are usually underpowered and the unintended effects are expected to be the same, regardless of the indication for the intervention \[[@CR56]--[@CR60]\]. Thirdly, our review avoids the problem of "overlapping" when a multiple-indication review consists of systematic reviews that include some, but not all, of the same studies \[[@CR56]\]. A limitation is the clinical heterogeneity and specifically the potential interaction with the type of condition. We therefore pre-specified condition subgroups for analysis.

A major limitation is also that a single expert drew up the list of pre-specified anticholinergic ADRs rather than a group of interdisciplinary experts. Some subjectivity in the selection of symptoms summarized in our primary outcome, anticholinergic ADRs, is therefore possible. A further limitation is the restriction to RCTs with a sample size of 100 or more study participants. This will decrease the power of our analyses and limit our ability to detect rare events \[[@CR57]\]. On the other hand, the combination of very small-scale studies with RCTs involving many participants would increase the heterogeneity between trials \[[@CR56]\]. Other sources of heterogeneity, such as age of participants, indication, dose, duration of treatment, and methodological quality of studies, will be analyzed carefully. Another potential limitation is that our search and selection process may miss relevant studies.

As this is the first systematic review of randomized controlled trials of anticholinergic ADRs of amitriptyline across multiple indications, no direct comparison with existing literature is possible. However, we identified systematic reviews on amitriptyline that focused on single indications and included an assessment of harms \[[@CR11], [@CR14], [@CR15], [@CR61]\]. We will be able to compare our results with those published in these reviews, as some of our pre-specified ADRs overlap.

The results of our multiple-indication review will support clinical decision-making in adult patients and help physicians decide whether the expected benefits of amitriptyline will outweigh potential harms arising from anticholinergic ADRs.

Supplementary information
=========================

 {#Sec13}

**Additional file 1.** Complete search strategy, \[Pdf document containing our complete search strategy\]

Ach

:   Anticholinergic

ADE

:   Adverse drug event

ADR

:   Adverse drug reaction

CNS

:   Central nervous system

DDD

:   Defined daily doses

EMA

:   European Medicines Agency

FDA

:   Food and Drug Administration

ICTRP

:   WHO International Clinical Trials Registry Platform

ISRCTN

:   International Standard Randomized Controlled Trial Number Register

mAChR

:   Muscarinic anticholinergic receptors

nAChR

:   Nicotinic anticholinergic receptors

OTC

:   Over-the-counter products

RCT

:   Randomized controlled trial

RoB

:   Risk of bias

SD

:   Standard deviation

TCA

:   Tricyclic antidepressant
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